ClinicalTrials.Veeva

Menu
A

ACRC Trials | Plano, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Lorundrostat
Laninamivir Octanoate
Pimecrolimus
Galcanezumab
Lasmiditan
Fesoterodine
Ciclesonide
Glycopyrronium
Diclofenac Sodium Gel
Sisunatovir

Parent organization

This site is a part of ACRC Trials

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 17 total trials

A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

a Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat (an aldosterone synthase inhibitor), administered on a background of a...

Enrolling
Hypertension
Drug: Placebo
Drug: lorundrostat Dose 2

The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults and the mai...

Active, not recruiting
Epstein-Barr Virus Infection
Biological: mRNA-1189
Biological: Placebo

The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to...

Active, not recruiting
COVID-19
Influenza
Biological: COVID-19 Vaccine
Biological: Investigational influenza vaccine

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prev...

Enrolling
Acute Gastroenteritis
Norovirus Acute Gastroenteritis
Biological: mRNA-1403
Biological: Placebo

The purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called varian...

Enrolling
COVID-19
SARS-CoV-2 Virus
Biological: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose
Biological: Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose

Trial sponsors

BioNTech logo
Pfizer logo
Lilly logo
Moderna logo
A
A
B
J
M
Sumitomo Pharma logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems